רווח תפעולי EBITDA: Journey Medical (DERM)

The current EBITDA figure from the GURU.Markets terminal provides a chart where the value 1.32 describes the current level for Journey Medical (DERM). This price action reflects adjustments for generic risks and FDA oversight. Stability is maintained by streamlined pharmacy supply chains and strict control over transportation conditions. Business efficiency is based on the full outsourcing of drug production to specialized partners, which eliminates supply downtime.

This indicator calculates cash flow from operating activities, excluding the impact of depreciation, tax liabilities, and the cost of debt. The EBITDA trend demonstrates the real liquidity of the business, where Journey Medical (DERM) patent protection of formulas and FDA approval create a sustainable barrier for competitors, directly converting drug exclusivity into stable growth of operating cash flow.